bilaterals.org logo
bilaterals.org logo

Intellectual property

Even before the World Trade Organization (WTO) lurched into its current state of crisis, bilateral FTAs had become a tool of choice for corporate and state interests seeking to expand intellectual property rights (IPR) standards. IPRs confer monopoly rights over intangible goods and services — methods of doing business on the internet, trademarks, computer programmes, designs, manufacturing processes, drug formulations or types of rice. They give IPR owners the right to prevent anyone from making or using their "creation". As such, they provide companies a direct tool to control a portion of the market, to block out competition and to fence off territories. Ironically, while IPR chapters are key aspects of many “free” trade and investment agreements, they are little more than protectionism for transnational corporations (TNCs), administered by governments. TNCs argue that without monopolies, there will be no innovation. Sharing should be banned; only capitalistic trade based on exclusive private property should be the norm.

Through FTAs, bilateral investment treaties (BITs) and other forms of direct agreements between countries, the US and Europe are insisting that the partner country adopt their standards of IPR protection and enforcement. This process has happened multilaterally via the WTO and the World Intellectual Property Organization. But it is now being pushed very aggressively through unilateral, bilateral and regional agreements — deals which go much further than the WTO’s Agreement on Trade-Related aspects of Intellectual Property rights (TRIPs). FTAs are setting “TRIPs-plus” standards.

The US imposes patents on plants and animals in its FTAs, while the EU and Japan, for the benefit of their biotech companies, push the UPOV Convention, a set of patent-like rules to prevent farmers from saving seeds. Meanwhile, pharmaceutical corporations have turned to FTAs as tools to impose stricter rules preventing the manufacture and trade of generic drugs. For many countries, and many peoples, these propositions are nothing short of revolutionary. Because it means they have to

 extend protection for branded drugs and limit parallel imports, hampering the availability of affordable generic medicines
 start patenting plants and animals, which means farmers cannot save seed or reproduce fish breeds or livestock
 get rid of screen quotas that give preference to the showing of local films
 start patenting computer software, to the detriment of local programmers and the creative open source movements now mushrooming up across the world as a cheaper alternative to Microsoft
 extend copyright protection, which already causes serious problems for students, libraries and educational institutions
 clamp down on piracy of popular consumer goods like digital products, clothing and music
 make IPR infringements criminal offences, even though IPR is part of civil law
and the list goes on.

Through IPRs, corporations seek monopoly control over vast areas of life. They expect that we should all regularly pay them licenses to use their products and to reimburse their research and development costs. Never mind all the public subsidies, tax breaks, university contract labour and so on that go into their research and development in the first place. IPR laws being pushed through bilateral channels make it public policy that countries should protect the TNCs, the real pirates.

Because of the serious implications that ‘TRIPs-plus’ IPR chapters of FTAs have for broad cross-sections of societies, in some anti-FTA struggles, such as the fightback against the US-Thailand FTA, farmers and people living with HIV/AIDS have joined together in their opposition of this new threat to their survival. Concerns have also been raised about the way in which the EU’s EPAs include TRIPs-plus provisions, while Indigenous Peoples in many countries continue to assert alternative frameworks for the use and sharing of traditional knowledge that challenge the capitalist, commodified logic of “intellectual property rights” enshrined in free trade and investment agreements.

More recently, a new development in transnational IPR enforcement has sparked opposition and controversy, including major protests in many European cities. In October 2011, after a secretive negotiations process, the Anti-Counterfeiting Trade Agreement (ACTA) was signed by a number of countries and will come into effect once six countries have ratified it. ACTA would potentially set up a new international legal framework for enforcing IPR. Opponents have criticized the agreement’s impact on privacy, freedom of expression and internet freedoms, and generic drug manufacturing.

last update: May 2012

Photo: Chile Mejor Sin TLC


FTAs facilitates biopiracy: The case of Peru
The United States has done it, and done it again. As part of the Free Trade Agreement (FTA) with Peru, the US has managed to wrest an amendment in the existing Intellectual Property laws that virtually ’facilitates biopiracy and hamper Peru’s position as a protector of traditional knowledge,’ reports SciDev.net
EU-ASEAN proposals on intellectual property too sweeping, say consumers
The proposed EU-Asean free trade policy on intellectual property rights protection is too sweeping, says a consumer group.
Revised laws ’could promote biopiracy’ in Peru
Modifications to intellectual property laws that the Peruvian government "rushed through" to enable the go-ahead of a free trade agreement (FTA) between Peru and the United States could facilitate biopiracy and hamper Peru’s position as a protector of traditional knowledge, say experts.
Strong EU trade provisions on IP seen as threat to poor nations’ medicines access
Efforts by the European Union to insert strong provisions on pharmaceutical patents in free trade agreements it is negotiating with India, Colombia, Peru and ASEAN could imperil access to medicines in developing countries, global public health activists have alleged.
Health protection in the Association Agreement between the European Union and the Andean Community
This new publication from Health Action International critically reviews the European proposals on intellectual property and discusses the impact they will have on access to essential medicines in the CAN countries.
Intellectual property in free trade agreements
FTAs often include intellectual property protection that is stronger than the World Trade Organisation requires (known as ‘TRIPS-plus’ protection). This book highlights the likely effects on developing countries of agreeing to these TRIPS-plus provisions, particularly those in US FTAs.
Opinion of the Office of the Ombudsperson of Costa Rica on the Budapest Treaty
The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of patent procedure is not in line with the norms and ethical principles of Costa Rica. Civil society, the scientific community and the different congregations should have had a more broad discussion on this Treaty including its ethical, environmental, social, economic and legal implications. Unfortunately, this did not happen and the decision to vote the US-DR-CAFTA, with its obligation for Costa Rica to accede to the Budapest Treaty, at referendum was not taken with a generalized prior informed consent.
Counterfeit democracy
The US Trade Representative’s officials say there is no reason to be worried: ACTA (a secret Anti-Counterfeiting Trade Agreement) won’t require more than existing US free trade agreements, they say. Meanwhile, business groups are explicit that they believe ACTA should do far more than existing US free trade agreements. Are they having their way?
Intellectual property in the EPA: broad scope, huge impact - Part III
Article 149 requires the EC Party and the Signatory CARIFORUM states to provide for the protection of plant varieties in accordance with the TRIPS Agreement and to consider, in this connection, accession to UPOV, 1991.
Intellectual property in the EPA: Broad scope huge impact - Part II
Jamaica enacted legislation for the protection of GIs through the Protection of Geographical Indications Act of 2004. However, protection under the law strictly complies with the standards laid out in the TRIPS Agreement and does not contemplate the "TRIPS plus" and "TRIPS extra" elements incorporated in the EPA.